The views, information, or opinions expressed in the Industry News RSS feed belong solely to the author and do not necessarily represent those of IDEX Health & Science and its employees.
Article obtained from Photonics RSS Feed.
Many antitumor drugs used in chemotherapy move around in the patient’s blood after intake. Healthy cells may be killed along with tumor cells, causing undesirable side effects. To avert potential “collateral damage” caused by antitumor drugs, a research team at City University of Hong Kong (CityU) has developed a small-molecule platinum(IV) anticancer prodrug called phorbiplatin. Phorbiplatin is shown to be inert in the dark, but it can be controllably activated under low-power red-light irradiation. As a prodrug, phorbiplatin only becomes pharmacologically active when it is activated inside the body.
Under short-period irradiation with a low intensity of red light (650 nm, 7 mW/cm2) and without any external…READ MORE